4D Molecular Therapeutics Inc
FDMTHealthcare|Biotechnology|USA
$12.30
-0.58 (-4.50%)
Tangible Book
$8.64
About
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Stock Price
+182.8%(1Y)
Pipeline Summary
10 total trials5
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
Terminated: 1Active: 5Recruiting: 4
Active Trials (9)
4D-150 in Patients With Diabetic Macular Edema
NCT05930561Diabetic Macular Edema
Phase 2Active
Enrollment: 72 participants
4D-310 in Adults With Fabry Disease and Cardiac Involvement
NCT05629559Fabry Disease
Phase 1Phase 2Recruiting
Enrollment: 18 participants
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
NCT04519749Fabry Disease
Phase 1Phase 2Active
Enrollment: 18 participants
4D-710 in Adult Patients With Cystic Fibrosis
NCT05248230Cystic Fibrosis Lung
Phase 2Recruiting
Enrollment: 30 participants
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
NCT04483440Choroideremia
Phase 1Active
Enrollment: 13 participants
BioScore
4.8/10
Cautious
Ownership
Recent Insider Trades
Bizily ScottSELL
2026-06-306,566 shares @ $14
Bizily ScottSELL
2026-06-239,810 shares @ $12
Kirn DavidSELL
2026-06-22114,746 shares @ $10.47
Kirn DavidSELL
2026-06-011,922 shares @ $10.02
Gupta AshooSELL
2026-03-20390 shares @ $8.61
Recent News
2026-06-29 12:29:30
2026-06-23 22:03:19
2026-06-18 00:00:13
Data last updated: Jul 13, 2026, 12:49 PM